Results 11 to 20 of about 6,997,331 (310)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

open access: yesRMD Open, 2023
Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD).
G. Burmester   +13 more
semanticscholar   +1 more source

Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care

open access: yesPharmaceuticals, 2023
Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation resulting in the production of some cytokines. Dupilumab radically changes the treatment of CRSwNP, but, considering its recent approval, it may be ...
Cosimo Galletti   +6 more
doaj   +1 more source

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?

open access: yesPharmaceutics, 2023
Antibacterial fluoroquinolones (FQs) are frequently used in treating infections. However, the value of FQs is debatable due to their association with severe adverse effects (AEs).
Aura Rusu   +3 more
semanticscholar   +1 more source

Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis.

open access: yesRadiotherapy and Oncology, 2023
BACKGROUND AND PURPOSE In recent years, the treatment landscape for breast cancer has undergone significant advancements, with the introduction of several new anticancer agents.
V. Salvestrini   +21 more
semanticscholar   +1 more source

Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.

open access: yesJournal of Allergy and Clinical Immunology, 2023
BACKGROUND Remibrutinib (LOU064), an oral, highly selective Bruton's tyrosine kinase inhibitor (BTKi), offers fast disease control in chronic spontaneous urticaria (CSU) patients who remain symptomatic despite second-generation H1-antihistamines.
V. Jain   +11 more
semanticscholar   +1 more source

Evaluation of the safety profile of COVID-19 vaccines: a rapid review

open access: yesBMC Medicine, 2021
Background The rapid process of research and development and lack of follow-up time post-vaccination aroused great public concern about the safety profile of COVID-19 vaccine candidates. To provide comprehensive overview of the safety profile of COVID-19
Qianhui Wu   +7 more
semanticscholar   +1 more source

Evaluation of the Safety Profile of the ASFV Vaccine Candidate ASFV-G-ΔI177L

open access: yesViruses, 2022
African swine fever (ASF) is the cause of a recent pandemic that is posing a threat to much of the world swine production. The etiological agent, ASF virus (ASFV), infects domestic and wild swine, producing a variety of clinical presentations depending ...
Xuan Hanh Tran   +10 more
semanticscholar   +1 more source

Safety Profile of Nutraceuticals Rich in Coumarins: An Update

open access: yesFrontiers in Pharmacology, 2022
Coumarins are a family of benzopyrones largely distributed in the natural kingdom, being present in the seeds, fruits, flowers, or roots of various plant species.
S. Hegheș   +5 more
semanticscholar   +1 more source

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients

open access: yesFrontiers in Oncology, 2022
PurposeProgrammed cell death protein 1 (PD-1) inhibitor plus apatinib is reported to be a promising strategy for advanced cancers. Moreover, a PD-1 inhibitor or apatinib exerts a certain efficacy in advanced colorectal cancer (CRC), whereas their ...
Dengdeng Pan   +7 more
doaj   +1 more source

Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2021
Significance Acceptance of vaccines has been on the decline in recent years. Despite encouraging early results for coronavirus vaccine trials, achieving herd immunity requires substantial uptake.
R. Kaplan, A. Milstein
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy